1.Fries HS, Nillus SJ, Petterson F. Epidemiology of secondary amenorrhea: II. A retrospective evaluation of etiology with specia regard to psychogenic factors and weight loss. Am J Obstet Gynecol 1974, 118:473.

2.Bachmann GA, Kemmann E. Prevalence of oligomenorrhea and amenorrhea in a college population. Am J Obstet Gynecol 1982; 144:98-102.

3.Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999;104:936-41.

4.Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53:804¿810.

5.Insler V, Melmed H, Mashiah S, Monselise M, Lunenfeld B, Rabau E. Functional classification of patients selected for gonadotropic therapy. Obstet Gynecol. 1968;32(5):620-6.

6.Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994;79:1470¿1475.

7.Block E. Quantitative morphological investigations of the follicular system in women: variations at different ages. Acta Anat 1952; 14:108.

8.Block E. A quantitative morphological investigation of the follicular system in newborn female infants. Acta Anat 1953; 17:201.

9.Simpson JL and Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet, 1999. 89(4): p. 186-200.

10.Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966;155:369-83.

11.Bione S, Sala C, Manzini C, Arrigo G, Zuffardi O, Banfi S, et al. A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet 1998;62(3):533¿541.

12.Espiner EA, Veale AM, Sands VE and Fitzgerald PH. Familial syndrome of streak gonads and normal male karyotype in five phenotypic females. N Engl J Med, 1970. 283(1): p. 6-11.

13.Davidoff F and Federman DD. Mixed gonadal dysgenesis. Pediatrics, 1973. 52(5): p. 725-42.

14.Manuel M, Katayama PK and Jones HW, Jr. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol, 1976. 124(3): p. 293-300.

15.Schellhas HF. Malignant potential of the dysgenetic gonad. Part 1. Obstet Gynecol, 1974. 44(2): p. 289-309.

16.Schellhas HF. Malignant potential of the dysgenetic gonad. II. Obstet Gynecol, 1974. 44(3): p. 455-62.

17.Villanueva AL and Rebar RW. Triple-X syndrome and premature ovarian failure. Obstet Gynecol, 1983. 62(3 Suppl): p. 70s-73s.

18.Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: The International Collaborative POF in Fragile X Study ¿ preliminary data. Am J Med Genetics 1999;83:322-5.

19.Hagerman RJ, Hagerman PJ. The fragile X premutation: Into the phenotypic fold. Curr Opin Genet Dev 2002;12:278-83.

20.Hagerman RJ, Leavitt BR, Farzin F et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004;74:1051-6.

21.Conway GS, Hettiarachchi S, Murray A, Jacobs PA. Fragile X premutations in familial premature ovarian failure. Lancet 1995;346:309¿310.

22.Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Hum Genet 2000;97:189-94.

23.Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001;27:159¿166.

24.De Baere E, Dixon MJ, Small KW, et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype-phenotype correlation. Hum Molec Gen 2001;10:1591-1600.

25.Fogli A, Rodriguez D, Eymard-Pierre E et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 2003;72:1544-50.

26.Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004;75:106-11.

27.Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829-36.

28.Biglieri EG, Herron MA, Brust N. 17-Hydroxylation deficiency in man. J Clin Invest 1966; 45:1946.

29.Goldsmith O, Solomon DH, Horton R. Hypogonadism and mineralocorticoid excess: the 17-hydroxylase deficiency syndrome. N Engl J Med 1967;277:673.

30.Mallin SR. Congenital adrenal hyperplasia secondary to 17-hydroxylase deficiency: two sisters with amenorrhea, hypokalemia, hypertension, and cystic ovaries. Ann Intern Med 1969; 70:69.

31.Rabinovici J, Blankstein J, Goldman B, et al. IN vitro fertilization and primary embryonic cleavage are possible in 17¿-hydroxylase deficiency despite extremely low intrafollicular 17¿-estradiol. J Clin Endocrinol Metab 1989;68:693.

32.Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560-6.

33.Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female hermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-92.

34.Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689.

35.Kaufman FR, Kogut MD, Donnel GN, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981; 304:994.

36.Aittomaki K, Dieguez Luccena JL, Pakarinen P, et al. Mutation in the follicle- stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:959.

37.Aittomaki K, Herva R, Stenman UH, et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996;81:3722.

38.Layman LC, Amede S, Cohen DP, et al. The Finnish follicle-stimulating hormone receptor gene mutation is rare in North American women with 46,XX ovarian failure. Fertil Steril 1998;69:300.

39.Liu JY, Gromoll J, Cedars MI. Identification of allelic variants in the follicle-stimulating hormone receptor genes of females with or without hypergonadotropic amenorrhea. Fertil Steril 1998;70:326.

40.Jones GS, de Moraes-Ruehsen M. A new syndrome of amenorrhea in association with hypergonadotropism and apparently normal ovarian follicular apparatus. Am J Obstet Gynecol 1969; 104:597.

41.Silva de Sa MF, Matthews MJ and Rebar RW. Altered forms of immunoreactive urinary FSH and LH in premature ovarian failure. Infertility, 1988. 11: p. 1-11.

42.Sluss PM and Schneyer AL. Low molecular weight follicle-stimulating hormone receptor binding inhibitor in sera from premature ovarian failure patients. J Clin Endocrinol Metab, 1992. 74(6): p. 1242-6.

43.Verp M. Environmental causes of ovarian failure. Semin Reprod Endocrinol, 1983. 1: p. 101-111.

44.Ash P. The influence of radiation on fertility in man. Br J Radiol, 1980. 53(628): p. 271-8.

45.Bisharah M and Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol, 2003. 188(2): p. 367-70.

46.Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986;45:443-59.

47.Green DM, Zevon MA, Lowrie G, Seigelstein N, Hall B. Congenital anomalies in children of patients who received chemotherapy for cancer in childhood and adolescence. N Engl J Med 1991;325:141-6.

48.Betterle C, Volpato M, Pedini B et al. Adrenal cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison¿s desease: comparison of immunofluorescence and immunoprecipitation assays. J Clin Endocrinol Metab 1999;84:618-22.

49.Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002;17:2096-2100.

50.Chiauzzi V, Cigorraga S, Escobar ME, et al. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins. J Clin Endocrinol Metab 1982; 54:1221.

51.van Weissenbruch MM, Hoek A, van Vliet-Bleeker I, et al. Evidence for existence of immunoglobulins that block ovarian granulosa cell growth in vitro. A putative role in resistant ovary syndrome. J Clin Endocrinol Metab 1991; 73:360.

52.Rebar RW. The thymus gland and reproduction: do thymic peptides influence reproductive lifespan in females? J Am Geriatr Soc 1982; 30:603.

53.Miller ME, Chatten J. Ovarian changes in ataxia telangiectasia. Acta Paediatr Scand 1967; 56:559.

54.Jacox HW. Recovery following human ovarian irradiation. Radiology 1939; 32:538.

55.Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976; 294:1143.

56.Koyama H, Wada J, Nishizawa Y, et al. Cyclophosphamide-induced failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39:1403.

57.Ataya KM, McKenna JA, Weintraub AM, et al. Treatment with LHRH agonist prevents chemotherapy induced follicular loss in rats. In: Abstracts of the 32nd annual meeting of the Society for Gynecologic Investigation, Arizona, 1985; 260.

58.Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. Fertil Steril 1975; 26:655.

59.Kim TJ, Anasti JN, Flack MR, Kimzey LM, Defensor RA, Nelson LM. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1997;89:777¿9.

60.Rebar RW, Cedars MI. Hypergonadotropic amenorrhea. In: Filicori M, Flamigni eds. Ovulation induction. Basic science and clinical advances. Amsterdam: Elsevier Science, 1994:115.

61.Lydic ML, Liu JL, Rebar RW, et al. Success of donor oocyte in in vitro fertilization-embryo transfer in recipients with and without premature ovarian failure. Fertil Steril 1996;65:98.

62.Warren MP. The effects of altered nutritional states, stress, and systemic illness on reproduction in women. In: Vaitukaitis J, ed. Clinical reproductive neuroendocrinology. New York: Elsevier Biomedical, 1981:177.

63.Rebar RW. The reproductive age: chronic anovulation. In: Serra GB, ed. The ovary. New York: Raven Press, 1983:217.

64.Klinefelter HF, Albright F Jr, Griswold GC. Experience with a quantitative test for normal or decreased amounts of follicle-stimulating hormone in the urine in endocrinological diagnosis. J Clin Endocrinol Metab 1943; 3:529.

65.Berga S, Mortola J, Gierton L, et al. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1989; 68:301.

66.Brundu B, Loucks TL, Adler LJ, Cameron JL, Berga SL. Increased cortisol in the cerebrospinal fluid of women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 2006 Feb.

67.Fairburn CG, Harrison PJ. Eating disorders. Lancet 2003;361:407-16.

68.Mehler PS. Clinical practice. Bulimia disorders. N Engl J Med 2003;349:875-81.

69.Bruch H. Perceptual and conceptual disturbances of anorexia nervosa. Psychosom Med 1962; 24:187.

70.Spitzer R, ed. Diagnostic and statistical manual of mental disorders, ed 4 :American Psychiatric Association, 1994:53.

71.Vigersky RA, Loriaux DL, Andersen MB. Anorexia nervosa: behavioral and hypothalamic aspects. Clin Endocrinol (Oxf ) 1976; 5:517.

72.Vigersky RA, Loriaux DL, Andersen AE, et al. Delayed pituitary hormone response to LRF and TRF in patients with anorexia nervosa and with secondary amenorrhea associated with simple weight loss. J Clin Endocrinol Metab 1976; 43:893.

73.Boyar R, Rosenfeld R, Kapen S, et al. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. J Clin Invest 1974; 54:609.

74.Sherman BM, Halmi KA, Zamudio R. LH and FSH response to gonadotropin-releasing hormone in anorexia nervosa: effect of nutritional rehabilitation. J Clin Endocrinol Metab 1975; 41:135.

75.Katz JL, Boyar R, Roffwarg H, et al. Weight and circadian luteinizing hormonesecretory pattern in anorexia nervosa. Psychosom Med 1978; 40:549.

76.Warren MP, Jewelewicz R, Dyrenfurth I, et al. The significance of weight loss in the evaluation of pituitary response to hypothalamic releasing hormones in patients with anorexia nervosa. J Clin Endocrinol Metab 1975; 40:601.

77.Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab 1975; 41:989.

78.Fries H. Studies on secondary amenorrhea, anorectic behavior, and body-image perception: importance for the early recognition of anorexia nervosa. In: Vigersky RA, ed. Anorexia nervosa. New York: Raven Press, 1977:163.

79.Mecklenberg RS, Loriaux DL, Thompson RH, et al. Hypothalamic dysfunction in patients with anorexia nervosa. Medicine (Baltimore) 1974; 53:147.

80.Warren MP, VandeWiele RL. Clinical and metabolic features of anorexia nervosa. Am J Obstet Gynecol 1973; 117:435.

81.Boyar RM, Hellman LD, Roffwarg H, et al. Cortisol secretion and metabolism in anorexia nervosa. N Engl J Med 1977; 296:190.

82.Casper RC, Chatterton RT Jr, Davis JM. Alterations in serum cortisol and its binding characteristics in anorexia nervosa. J Clin Endocrinol Metab 1979; 49:406.

83.Takahara J, Hosogi H, Yunoki S, et al. Hypothalamic pituitary adrenal function in patients with anorexia nervosa. Endocrinol Jpn 1976; 23:451.

84.Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa: pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 1986; 314:1335.

85.Vigersky RA, Andersen AE, Thompson RH, Loriaux DL. Hypothalamic dysfunction in secondary amenorrhea associated with simple weight loss. N Engl J Med 1977; 297:1141.

86.Yen SSC, Rebar R, VandenBerg G, Judd H. Hypothalamic amenorrhea and hypogonadotropinism: responses to synthetic LRF. J Clin Endocrinol Metab 1973; 36:811.

87.Van der Walt LA, Wilmsen EN, Jenkins T. Unusual sex hormone patterns among desert-dwelling hunter-gatherers. J Clin Endocrinol Metab 1978; 46:658.

88.Rebar RW, Cumming DC. Reproductive function in women athletes. JAMA 1981; 246:1590.

89.Cumming DC, Rebar RW. Exercise and reproductive function in women: a review. Am J Ind Med 1983; 4:113.

90.American College of Sports Medicine. The female athlete triad: disordered eating, amenorrhea, and osteoporosis. Call to action. Sports Med Bulletin 1992;27:4.

91.Miller KK, Parulekar MS, Schoenfeld E, et al. Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab 1998;83:2309-12.

92.Warren MP, Voussoughian F, Geer EB, Hyle EP, Adberg CL, Ramos RH. Functional hypothatlamic amenorrhea: hypoleptinemia and disordered eating. J Clin Endocrinol Metab 1999;84:873-7.

93.Thong FS, McLean C, Graham TE. Plasma leptin in female athletes: relationship with body fat, reproductive, nutritional, and endocrine factors. J Appl Physiol 2000;88:2037-44.

94.Laughlin GA, Yen SSC. Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. J Clin Endocrinol Metab 1997;82:318-21.

95.Bullen BA, Skrinar GS, Beitins IZ, et al. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985; 312:1349.

96.Beitins IZ, McArthur JW, Turnbull BA, et al. Exercise induces two types of human luteal dysfunction: confirmation by urinary free progesterone. J Clin Endocrinol Metab 1991; 72:1350.

97.Rogol AD, Weltman A, Weltman JY, et al. Durability of the reproductive axis in eumenorrheic women during 1 year of endurance training. J Appl Physiol 1992; 72:1571.

98.Drinkwater BL, Nilson K, Chestnut CH III, et al. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 1984; 311:277.

99.Marcus R, Cann C, Madvig P, et al. Menstrual function and bone mass in elite women distance runners. Ann Intern Med 1985; 102:158.

100.Snead DB, Weltman A, Weltman JY, et al. Reproductive hormones and bone mineral density in women runners. J Appl Physiol 1992; 72:2149.

101.Myerson M, Gutin B, Warren MP, et al. Total body bone density in amenorrheic runners. Obstet Gynecol 1992; 79:973.

102.Jonnavithula S, Warren MP, Fox RP, Lazaro MI. Bone density is compromised in amenorrheic women despite return of menses. A 2-year study. Obstet Gynecol 1993; 81:669.

103.Schwartz B, Cumming DC, Riordan E, et al. Exercise-associated amenorrhea: a distinct entity? Am J Obstet Gynecol 1981; 141:662.

104.Warren MP. The effects of exercise on pubertal progression and reproductive function in girls. J Clin Endocrinol Metab 1980; 51:1150.

105.Villanueva AL, Schlosser C, Hopper B, et al. Increased cortisol production in women runners. J Clin Endocrinol Metab 1986; 63:126.

106.Loucks AB, Mortola JF, Girton L, Yen SSC. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic pituitary-adrenal axes in athletic women. J Clin Endocrinol Metab 1989; 68:402.

107.Loucks AB, Laughlin GA, Mortola JF, et al. Hypothalamic-pituitary-thyroidal function in eumenorrheic and amenorrheic athletes. J Clin Endocrinol Metab 1992; 75:514.

108.Lachelin GCL, Yen SSC. Hypothalamic chronic anovulation. Am J Obstet Gynecol 1978; 130:825.

109.Vaitukaitis J, Becker R, Hansen J, Mecklenburg R. Altered LRF responsiveness in amenorrheic women. J Clin Endocrinol Metab 1974; 39:1005.

110.Rakoff JS, Rigg LA, Yen SSC. The impairment of progesterone-induced pituitary release of prolactin and gonadotropin in patients with hypothalamic chronic anovulation. Am J Obstet Gynecol 1978; 130:807.

111.Suh BY, Liu JH, Berga SL, et al. Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab 1988; 66:733.

112.Sachar EJ, Hellman L, Roffwarg H, et al. Disrupted 24 hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973; 28:19.

113.Amsterdam JD, Winokur A, Abelman E, et al. Cosyntropin (ACTH ¿1¿24) stimulation test in depressed patients and healthy subjects. Am J Psychiatry 1983; 140:907.

114.Quigley ME, Sheenah KL, Casper RF, Yen SSC. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1908; 50:949.

115.Ballenger JC, Post RM, Jimerson DC, et al. Biochemical correlates of personality traits in normals: an exploratory study. Personality Individ Differ 1983; 4:615.

116.Brown E, Bain J, Lerner P, Shaul D. Psychological, hormonal, and weight disturbances in functional amenorrhea. Am J Psychiatry 1983; 28:624.

117.Schreiber C, Florin I, Rost W. Psychological correlates of functional secondary amenorrhea. Psychother Psychosom 1983; 39:106.

118.Fava GA, Trombini G, Grandi S, et al. Depression and anxiety associated with secondary amenorrhea. Psychosomatics 1984; 25:905.

119.Liu JH, Yen SSC. The use of gonadotropin-releasing hormone for the induction of ovulation. Clin Obstet Gynecol 1984; 27:975.

120.Martin K, Santoro N, Hall J, et al. Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990; 71:1081A.

121.Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004;351:987-97.

122.Hay PJ, Bacaltchuk J. Psychotherapy for bulimia anorexia and binging (Cochrane Review). In: The Cochrane Library, Issue 2, 2004, Chichester, UK: John Wiley & Sons, Ltd.

123.Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944; 48:203.

124.Odell WD. Isolated deficiencies of anterior pituitary hormones: symptoms and diagnosis. JAMA 1966; 197:1006.

125.Spitz IM, Diamant Y, Rosen E, et al. Isolated gonadotropin deficiency: a heterogeneous syndrome. N Engl J Med 1974; 290:10.

126.Tagatz G, Fialkow PJ, Smith D, Spadoni L. Hypogonadotropic hypogonadism associated with anosmia in the female. N Engl J Med 1970; 283:1326.

127.De Morsier G. Studies in cranio-encephalic dysraphia. I. Agnesia of the olfactory lobe (lateral telencephaloschisis) and of the callous and anterior commissures (median telencephaloschisis); olfacto-genital dysplasia. Schweiz Arch Neurol Psychiatr. 1954; 74(1-2):309-61.

128.Schwanzel-Fukuda M, Pfaff DU. Origin of luteinizing hormone-releasing hormone neurons. Nature 1989; 338:161.

129.Klingmuller D, Dewes W, Krahe T, et al. Magnetic resonance imaging of the brain in patients with anosmia and hypothalamic hypogonadism (Kallmann's syndrome). J Clin Endocrinol Metab 1987; 65:581.

130.Goldenberg RL, Powell RD, Rosen SW, et al. Ovarian morphology in women with anosmia and hypogonadotropic hypogonadism. Am J Obstet Gynecol 1976; 126:91.

131.Crowley WF Jr, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH). J Clin Endocrinol Metab 1980; 51:173.

132.Yen SSC, Rebar RW, VandenBerg G, et al. Pituitary gonadotropin responsiveness to synthetic LRF in subjects with normal and abnormal hypothalamic-pituitary-gonadal axis. J Reprod Fertil 1973; 20:137.

133.Yeh J, Rebar RW, Liu JH, Yen SSC. Pituitary function in isolated gonadotropin deficiency. Clin Endocrinol 1989; 31:375.

134.Molitch ME, Reichlin S. Hyperprolactinemic disorders. DM 1982; 28:1.

135.Lachelin GCL, Abu-Fadil S, Yen SSC. Functional delineation of hyperprolactinemic-amenorrhea. J Clin Endocrinol Metab 1977; 44:1163.

136.Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303:1511.

137.Leblanc H, Lachelin GC, Abu-Fadil S, Yen SSC. Effects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 1976; 43:668.

138.Board JA, Storlazzi E, Schneider V. Nocturnal prolactin levels in infertility. Fertil Steril 1983; 36:720.

139.DeVane GW, Gusick DS. Bromocriptine therapy in normoprolactinemic women with unexplained infertility and galactorrhea. Fertil Steril 1986; 46:1026.

140.Suginami H, Hamada K, Yano K, et al. Ovulation induction with bromocriptine in normoprolactinemic anovulatory women. J Clin Endocrinol Metab 1986; 62:899.

141.Sheehan HL, Davis JC. Pituitary necrosis. Br Med Bull 1968; 24:59.

142.Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.

143.Rebar RW, Judd HL, Yen SSC, et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57:1320.

144.DeVane GW, Czekala NM, Judd HL, Yen SSC. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.

145.Buckler HM, McLachlan RI, MacLachlan VB, et al. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration. J Clin Endocrinol Metab 1988; 66:798.

146.Yen SSC. The polycystic ovary. Clin Endocrinol (Oxf ) 1980; 12:177.

147.Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992, p. 377.

148.ESHRE/ASRM. Revised 2003 consensus on diagnostic crieteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.

149.The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.

150.Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235.

151.Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovarian syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078.

152.Franks S, Gharani N, Waterworth D. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641.

153.Legro RS, Driscoll D, Strauss JF III, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956.

154.Taylor SI, Dons RF, Hernandez E, et al. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med 1982; 97:851.

155.Bar RS, Muggeo M, Roth J, et al. Insulin resistance, acanthosis nigricans, and normal insulin receptors in a young woman: evidence for a postreceptor defect. J Clin Endocrinol Metab 1978; 47:620.

156.Erickson GF, Hsueh AJW, Quigley ME, et al. Functional studies of aromatase activity in human granulose cells from normal and polycystic ovaries. J Clin Endocrinol Metab 1979;49:514.

157.Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113.

158.Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non-obese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57:356.

159.Dunaif A. Insulin resistance ad the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774.

160.Geffner ME, Kaplan SA, Bersch N, et al. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian sex steroid secretion. Fertil Steril 1986; 45:327.

161.Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest 1989; 83:23.

162.Velazquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392.

163.Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic reproductive abnormalities in the polycystic ovary syndromw. J Clin Endocrinol Metab 1996;81:3299.

164.Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic overy syndrome. J Clin Endocrinol Metab. 1997;82:2108.

165.Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Eng L Med 1999;340:1314.

166.Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984; 41:719.

167.Elkind-Hirsch KE, Valdes CT, McConnell TG, Malinak LR. Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women. Fertil Steril 1991; 55:486.

168.Smith S, Ravnikar V, Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. Fertil Steril 1987; 48:72.

169.Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol 1989; 31:757.

170.Nestler JC, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68:1027.

171.Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 70:699.

172.Dale PO, Tanbo T, Djoseland O, et al. Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol 1992; 126:132.

173.Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987; 8:132.

174.Bergh C, Carlsson B, Olsson J-H, et al. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993; 59:323.

175.Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83.

176.Conover CA, Lee PDK, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74:1355.

177.Guzick DS, Wing R, Smith D. Endocrine consequences of weight loss in obese, hyperandrogenic anovulatory women. Fertil Steril 1994;61:598.

178.Anderson P, Selifeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44;611.

179.Jakubowicz DJ, Nestler JE. 17¿-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556.

180.Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269.

181.Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 1998;338:867.

182.Greenblatt E, Casper RF. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987; 156:279.

183.Daniell JF, Miller W. Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril 1989; 51:232.

184.Smals AGH, Kloppenborg PWC, Benraad TJ. Plasma testosterone profiles in Cushing's syndrome. J Clin Endocrinol Metab 1977; 45:240.

185.Owings MF, Kozak LJ. Ambulatory and inpatient procedures in the United States, 1996. National Center for Health Statistics. Vital Health Stat 13(139). 1998 pp 1-127.

186.Gambone JC, Reiter RD, Lench JB, Moore JB. The impact of a quality assurance process on the frequency and confirmation rate of hysterectomy. Am J Obstet Gynecol 1990;163:545-50.

187.Lepine LA, Hillis SD, Marchbanks, PA, Kovnim LM, Morrow B, Kieke BA, Wilcox LS. Hysterectomy Surveillance ¿ United States, 1980-1993. In: CDC Surveillance Summaries, Aug 8, 1997 MMWR 1997;46(No. SS-4); 1-15.

188.Falcone T, Desjardins C, Bourque J, Granger L, Hemmings R, Quiros E. Dysfunctional uterine bleeding in adolescents. J Reprod Med 1994;39:761-4.

189.Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from National Health Interview Survey, 1984-1992. Am J Public Health 1996;86:195-9.

190.deVries LD, Dijkhuizen FB, Mol BW, Brolmann HA, Moret E, Heintz AP. Comparison of transvaginal sonography, saline infusion sonography, and hysteroscopy in premenopausal women with abnormal uterine bleeding. J Clin Ultrasound 2000; 28:217-23.

191.Widrich T, Bradley LD, Mitchinson AR, Collinc RL. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol 1996;174:1327-34.

192.Saidi, MH, Sadler RK, Theis VD, Akright BD, Farhart SA, Villanueva GR. Comparison of sonography, sonohysterography, and hysteroscopy for evaluation of abnormal uterine bleeding. J Ultrasound Med 1997;16:587-91.

193.Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynceol. 2000;96:913-20.

194.Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Cochran Review). Cochrane Database Syst Rev. 2002, (1):CD000400.

195.Crossignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, DeGiorgi O. Levonorgestrel-releasing intrauterine devide versus hysteroscopic endometrial resection in the treatment of hysteroscopic dysfunctional uterine bleeding. Obstet Gynecol 1997; 90:257-63.

196.Bonner J, Sheppard BL. Treatment of menorrhagia during menstration: randomized, controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579-82.

197.Lethaby A, Farquhar C, Cooke I. Antifilrinolytics for heavy menstrual bleeding (Cochran Review). In: Cocharn Database Syst Rev 2000;4:000249.

198.Thomas EJ, Okuda KJ, and Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1996;103:18-21.

199.Vercellini P, Oldani S, Yaylayan L, Zaina B, De Giorgi O, Crossignani PG. Randomized comparison of vaporizing electrode and cutting loop for endometrial ablation. Obstet Gynecol 1999;94:521-7.

200.Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders the MISTLETOE study. Minimally invasive surgical techniques ¿ laser, endothermal, or endoresection. Br J ObstetGynecol 1997;102;1351-9.

201.Meyer WR, Walsh BW, Grainger DA, Peacock LM, Loffler FD, Steege JF. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol 1998;92:98-103.

202.Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Obstet Gynecol, 2000 Aug; 96(2):266-70.

203.Sowter MC, Singla AA, Lethaby A. Pre-operative thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Cochran Database Syst Rev 2000; (2): CD00124.

204.Lethaby A, Sheppard S, Cooke I, Farquher C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochran Database Syst Rev 2000;(2):CD00329.

205.Aberdeen Endometrial Ablation Trials Group. A randomized trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding outcome at four years. Br J Obstet Gynaecol 1999;106:360-6.

206.Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochran Database Syst Rev 2000;(2):CD000402.